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Dose escalation or intensification by radiation is built on the premise 
that  higher biological doses will lead to better local tumour control. 
Obviously, the ultimate goal should be to obtain uncomplicated cures.  
From a theoretical point of view, both the improvement of techniques 
or the ability to understand the biology of radiation damage to the 
normal tissues resulting in appropriate patient selection and 
pharmacological interventions will increase the therapeutic ratio. 
Radiotherapy techniques have improved dramatically over the last 
decade, now enabling to use IMRT and Volumetric Modulated Arc 
Radiotherapy in daily practice. This results in the possibility to deliver 
high dose radiation in patients that once were deemed to receive 
palliative doses. The on-going developments in on-line adaptation will 
further improve this evolution. Other new developments include dose 
re-distribution studies in which the whole PTV no longer receives an 
homogeneous dose, but a higher dose is delivered on the basis of 
molecular imaging characteristics. In many patients, this allows 
further dose escalation with equal doses to normal tissues. However, 
in the PET-boost study, the mediastinal structures were the most 
frequent dose-limiting (van Elmpt et al; Radiother Oncol 2012). Proton 
therapy has been shown to allow further dose escalation in many 
theoretical planning studies.       
However, knowledge about the biological characteristics of OARs of 
individual patients would allow stratification into risk groups for side 
effects and possibly pharmacological interventions as well. Many 
studies have been reported on the relation between SNPs and side 
effects of radiotherapy. Most results were retrospective and could not 
be replicated in independent prospective validation cohorts (Barnett 
GC et al. Lancet 2012). With better study design and standardisation 
as for instance advocated by the Radiogenomics Consortium, and 
newer techniques such as GWAS, robust genetic features for radiation 
toxicity may emerge (Talbot CJ et al. Br J Cancer 2012).  
In conclusion, dose escalation depends both on optimal techniques 
and biology, but much research remains to be done in order to build 
models and workflows with proven clinical value (Lambin et al. Nat 
Rev Clin Oncol. 2012). 
 
 SYMPOSIUM: RIGHT NOW CAN CLINICAL CHOICES BE 
BASED ON EVIDENCES FROM LARGE DATABASES?  
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Clinical guidelines are recommendations on how healthcare 
professionals should care for people with specific conditions. The 
recommendations are based on the best available evidence. Until 
recently, the highest level of evidence was considered to be derived 
from randomized clinical trials, or even better, meta-analyses of 
randomized clinical trials. Undoubtedly, clinical trials are essential 
but many factors limit their success, such as the costs of long-term 
follow-up, and participants often not being representative of the 
general population. In the last decade, realization that population 
based databases may help in evaluating the generalizability of clinical 
guidelines has emerged. However, one has to be aware of the pitfalls 
of population based databases. Even population-based databases can 
contain a selection bias, and the assumption that the patients in the 
database are a valid representation of the target group should always 
be tested. In addition, the accuracy of the data has to be monitored, 
as well as the setting in which the data have been collected. To make 
optimal use of population-based databases, comorbidity should be 
reported as well. For radiotherapy in particular, registration of the 
treatment details and information on long-term follow-up should be 
provided to ensure adequate evaluation of the treatment effects.  So 
far, most databases have been initiated by the surgical community or 
generated by for example National Health Services. The underlying 
motive has not so much been development of clinical guidelines, but 
more to implement a clinical auditing system that aims to provide a 
greater level of insight into the process and outcomes of patients who 
undergo medical treatment and to continuously improve this. In order 
to start this improvement cycle (the ‘audit cycle’), it is important to 
identify which quality aspects are important and where improvements 
are required. The most important objective of clinical auditing is to 
initiate a cycle for improvement on a national, regional and local 
level. The feedback that medical specialists are given regarding the 
care that they provide forms the catalyst for improvement initiatives. 
 Several European countries have implemented such audit for 
colorectal cancer, providing much inside in current standards of care. 
It has already resulted in demonstrable improvements in the 
treatment provided to colorectal patients. For example, 
improvements in adequate pre-operative imaging in colon cancer 
patients have been observed, as well as increases in the number of 
patients suffering from rectal carcinoma that were discussed in a 
multidisciplinary team prior to operation. This has resulted in an 
increase of administration of (neo-)adjuvant radiotherapy and an 
improved standard of pathological reporting regarding, for example, 
number of lymph nodes examined and the reporting of circumferential 
resection margins (CRM).  
In addition, results from the population based databases have 
identified the problems concerning frail elderly people. Half of 
patients suffering from bowel cancer are older than 70 years of age. 
Many of these elderly people have comorbidities and are vulnerable to 
both the increased occurrence of complications and the consequences 
thereof. These risks have been definitely confirmed in clinical audits 
and have resulted in awareness that although clinical guidelines 
should be suitable for most patients with a specific condition, 
identification of specific risk groups is warranted. 
In conclusion: clinical auditing is absolutely necessary to evaluate and 
refine clinical guidelines. However, there will always be a need for 
clinical trials to facilitate practice changing research. 
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“Radiomics” refers to the extraction and analysis of advanced 
quantitative imaging features in high throughput from medical 
images, including computed tomography (CT), positron emission 
tomography (PET) and magnetic resonance imaging (MRI) (Lambin et 
al. EJC 2012; ww.radiomics.org). Importantly, these features are 
designed to be extracted from standard-of-care images, leading to a 
very large potential subject pool.  Radiomic data are in a mineable 
form that can be used to build descriptive and predictive models. The 
core hypothesis of radiomics is that these models, which can include 
biological or medical ata, can provide valuable diagnostic, prognostic 
or predictive information.Also, relating image features to phenotypes 
or gene-protein signatures is being investigated. The radiomics 
enterprise can be divided into four processes, each with its own 
challenges that need to be overcome:  (1) image acquisition and 
reconstruction,(2) image segmentation and rendering, (3) feature 
extraction and qualification,(4) bioinformatic analyses. Each step, 
especially involving large datasets,poses unique challenges. The focus 
of this presentation will be on the predictive value of CT & FDG-PET 
radiomics features of non-small cell lung cancer and head and neck 
cancer, complemented by preclinical tumour data. Finally we will 
describe the current and potential applications of radiomics to other 
problems in oncology. 
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Over the past decade the progress in individualized medicine has 
posed major challenges also in radiotherapy of cancer diseases. The 
development of models for decision making seems crucial for taking 
advantage of inter- and intra-patient variability to maximize the 
therapeutic index in RT by increased tumour control and decreased 
normal tissue complications. Models depend to a high degree on 
validated predictors such as the tumour dose-response relationship, 
among many others. 
Using modern RT delivery techniques like IMRT and volumetric arc 
therapy in combination with in-room image-guidance complex dose 
distributions are administered to cover target and spare organs at risk 
with high spatial precision. However, the increasing use of volumetric 
imaging such as cone-beam CT during the fractionated treatment 
course allow for detection of changes in the patient anatomy and, 
thus, detect the temporal aspects in the delivered dose distribution 
which might deviate from the planned one. Utilization of delivered 
dose-response relationships is expected to increase the accuracy of 
prediction models. 
Several aspects are involved in the analysis of the CBCT image sets. 
The inferior image quality due to artefacts compared to conventional 
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CT may hamper contouring and dose calculation accuracy. Although 
not in widespread routine use, deformable image registration (DIR), 
preferable unsupervised, is used for auto-segmentation of 
organs/volumes based on those delineated on a reference planning 
CT. Using the daily pre-treatment registrations between planning CT 
and CBCT the delivered dose at each fraction can be recalculated on 
the CBCT anatomy with proper calibration of the systems. Based on 
DIR, accumulation of the dose can be performed from day to day, and 
delivered dose can be compared directly with the planned dose, and 
dose-volume histograms for OAR can be evaluated. Alternatively, the 
consecutive DIRs can be combined to represent a mean deformation 
vector field which can be applied to the planning CT with planned 
dose distribution to obtain a measure of delivered dose.  For dose-
response relations, the accumulated delivered dose needs to be 
combined with validated clinical outcome measures.  
   
 LOOK INSIDE: ADAPTIVE RADIOTHERAPY IN PRACTICE  
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Head and neck tumors become on the average 40% and 70% smaller 
after 2 and 4 weeks of radio(chemo)therapy, respectively. Tumor 
response, alterations in non-tumor anatomy and treatment-induced 
toxicity like weight loss or edema, cause a mismatch between pre-
treatment planned dose distributions on the one hand and the shapes 
of tumor and organs-at-risk (OARs) on the other hand. By regularly 
adapting the treatment to changing anatomy, avoidance of OARs is 
maintained during the whole treatment. By simultaneously updating 
dose-painting to changing biology, optimal targeting of radioresistant 
parts of the tumor is better secured. To investigate this dual 
hypothesis, dosimetrical effects of adaptive (ART) and non-adaptive 
(RT) dose-painted radiotherapy were investigated for 10 patients with 
head-and-neck cancer. Three treatment-phases were preceded by a 
planning PET/CT scan. In ART, phases II and III were planned using 
PET/CT2 and PET/CT3, respectively. In RT, the phase-I plan on 
PET/CT1, was used to calculate dose-distributions on PET/CT2 and 
PET/CT3. Deformable image co-registration was used to sum dose 
distributions and to propagate regions-of-interest (ROIs) drawn on 
PET/CT1 to PET/CT2, PET/CT3 and to a last-treatment-day CT-scan 
(CT4).  Inaccurately deformed ROIs were manually adjusted if 
necessary. In target ROIs, ART provided higher minimum and lower 
maximum doses than RT and re-matched dose-painting. For OARs, ART 
improved critical dose/volume parameters. ART achieved average 
reduction of 4.6-7.1% in the parotids’ median dose (p<0.05) and 3% in 
the swallowing structures’ mean dose (p=0.06). Improvements of 
dose/volume parameters by ART were more pronounced in individual 
patients reaching 24.4% minimum-dose increase in elective neck PTV 
and 29.5% mean-dose decrease in swallowing structures.  
Conclusion: Compared to RT, ART readjusts dose-painting, increases 
minimum and decreases maximum doses in target volumes and 
improves dose/volume parameters of OARs. Reporting population-
average effects in ROIs underestimates the patient-individual benefits 
of ART. 
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Currently, in external beam radiotherapy of locally advanced cervical 
cancer, a large safety margin around the tumour is needed to 
compensate for potentially large day-to-day variations in the target 
position and shape, as e.g. induced by bladder and rectum volume 
changes. At Erasmus MC we have developed an individualized adaptive 
RT approach resulting in significant margin reductions (Bondar et al. 
IJROBP 2012 Aug 1;83(5):1617-23). In the treatment preparation 
phase, patients are stratified in two groups with small or large 
bladder-volume induced tumour motion. For the first group, a single 
IMRT plan is created with an individualized small margin. For the 
second group two IMRT plans are created, adequate for tumour 
positions and shapes corresponding to smaller and larger bladder 
volumes. Every treatment day, the best fitting plan is selected based 
on an in-room acquired Cone Beam CT scan (CBCT), showing internal 
anatomy and markers implanted around the primary tumour. 
The first part of this presentation will review the rationale of library-
based Plan-of-the-Day strategies for this treatment site. Using data of 
14 patients with two series of variable bladder filling CT scans 
(acquired pretreatment and after 40 Gy), we demonstrated the 
benefit of 1) individualizing the required margin by using an 
individualized internal target volume (ITV) and 2) of using two 
separate ITVs for patient with large cervix-uterus motion. 
In the second part of the presentation, we will provide inside in 
practical issues concerning the implementation of the library-based 
Plan-of-the-Day strategy. The following issues in the preparatory 
phase will be discussed: 1) the acquisition of an empty and full 
bladder filling CT scan, 2) the choice of the number IMRT plans in the 
plan library, 3) the creation of the ITVs, 4) the implantation of 
markers around the primary tumour as an aid to quickly verify the 
position of the cervix at the treatment unit, and 4) the addition of a 
motion-robust backup plan to the plan library.  
Next, inside will be provided in the image-guidance and plan-selection 
procedure at the linear accelerator. In this procedure daily CBCT 
scans are acquired for online patient-setup correction and assessment 
of the position of the uterus and markers (XVI software, Elekta AB). 
Contours of 10-mm margins around the markers, PTV, and ITV are 
projected on the bone-matched CBCT scan. The bony anatomy is used 
because of the nodal CTV to be treated. An intervention decision tree 
coaches RTTs through the whole plan selection procedure. Plan 
selection is completed by an online patient setup correction (based on 
the bony-anatomy match), followed by the manual selection of the 
plan of the day in the treatment record and verify system. In the final 
part of this presentation, an evaluation of the clinical protocol will be 
presented. 
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In state of the art image guided, intensity modulated radiotherapy 
(IGIMRT) of primary prostate cancer, inter-and intra-fractional 
movements of the organ are still the main reason for safety margins 
between the clinical target volume (CTV) and the planning target 
volume(PTV). Margins and side effects in neighbouring 
structures hinder dose escalations. Even if daily pre-treatment 
imaging and faster rotational treatment delivery (VMAT) are 
performed, intra-fractional patient and target motion are limiting 
factors for a successfull radiotherapy. 
Different spacer materials (injected gels, balloons) can be used to 
enlarge the distance between the high dose region (PTV) and an organ 
at risk (rectum). It was tested, if the bulky volume of spacers can also 
contribute to a reduction of uncertainties by constraining inter- and 
intrafractional movements. Preliminary results of our own 
investigations on >50 spacer patients show that there may be no 
significant reduction of movements, neither interfractionally nor 
intrafractionally. 
 
